Results 131 to 140 of about 117,653 (216)

An update on recombinant vaccines against leishmaniasis. [PDF]

Indian J Med Res
Shital S, Madan E, Selvapandiyan A, Kumar Ganguly N.   +3 more
europepmc   +1 more source

Production of recombinant human granulocyte‐macrophage colony‐stimulating factor in thermoinducible E. coli: Tuning inclusion body architecture and protein yield via dissolved oxygen control

Journal of Chemical Technology &Biotechnology, EarlyView.
Abstract BACKGROUND Recombinant protein expression in Escherichia coli frequently results in the formation of inclusion bodies (IBs), which provide high protein accumulation but often require additional steps to recover functional protein. Although culture conditions strongly influence IB physicochemical and structural characteristics, the impact of ...
Ximena Gómez‐Gil, Norma A Valdez‐Cruz, Sara Restrepo‐Pineda, Nuria Sánchez‐Puig, Rafael Vázquez‐Duhalt, Rubén D Cadena‐Nava, Néstor O Pérez, Mauricio A Trujillo‐Roldán   +7 more
wiley   +1 more source

Designing multifunctional recombinant vaccines: an engineering strategy based on innovative epitope prediction-guided splicing. [PDF]

Theranostics
Wang Z, Yang X, Wei X, Shi L, Wang X, Zhuo Z, Su H, Wu W, Cao YJ.   +8 more
europepmc   +1 more source

Adaptive Immunity in Marsupials

Journal of Experimental Zoology Part A: Ecological and Integrative Physiology, EarlyView.
Comparison of the marsupial and eutherian adaptive immune systems. ABSTRACT Marsupials diverged from eutherian mammals 125–160 million years ago. Although evolutionarily distinct, both groups of mammals can produce complex adaptive immune responses to antigens with several key differences.
Cassandra L. Jol, Hayley J. Stannard, Julie M. Old   +2 more
wiley   +1 more source

Hydroxamic Acids as HDAC Inhibitor Drug Leads for Malaria

Medicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a global health threat, with an estimated 282 million cases and 610,000 malaria‐associated deaths reported in 2024. Most mortality is due to infection by Plasmodium falciparum parasites, with the highest burden occurring in Sub‐Saharan Africa.
Wisam A. Dawood, Jacinta R. Macdonald, Christian Anzenhofer, Tina S. Skinner‐Adams, Robert C. Reid, Thomas Kurz, David P. Fairlie, Katherine T. Andrews   +7 more
wiley   +1 more source

Plasmepsins as Antimalarial Drug Targets—Then, Now, and the Future

Medicinal Research Reviews, EarlyView.
ABSTRACT Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D‐like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential
Brad E. Sleebs
wiley   +1 more source

Advances and challenges in experimental models for Epstein–Barr virus research

mLife, EarlyView.
Abstract Epstein–Barr virus (EBV), the first identified human oncovirus, is a ubiquitous γ‐herpesvirus etiologically linked to diverse malignancies, lymphoproliferative disorders, and autoimmune diseases. Experimental models are pivotal for unraveling the infection and pathogenesis mechanisms, life cycle regulation, as well as development and ...
Gulimire Wufuer, Jiabao Tang, Tingdong Li, Shengxiang Ge, Jun Zhang, Ningshao Xia   +5 more
wiley   +1 more source

A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector. [PDF]

Sci Rep, 2019
Ohtsuka J, Fukumura M, Furuyama W, Wang S, Hara K, Maeda M, Tsurudome M, Miyamoto H, Kaito A, Tsuda N, Kataoka Y, Mizoguchi A, Takada A, Nosaka T.   +13 more
europepmc   +1 more source

Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies

Rheumatology &Autoimmunity, EarlyView.
In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley   +1 more source

Applications of chitosan derivatives as adjuvants for nanoparticle‐based vaccines: A comprehensive review

Smart Molecules, EarlyView.
This review highlights how chitosan derivatives enhance nanoparticle‐based vaccines through superior stability, mucoadhesion, and immune modulation. By triggering robust mucosal, humoral, and cellular responses, these biocompatible polymers serve as a transformative platform for next‐generation immunotherapeutics and safe and effective vaccine delivery
Sayantani Dasgupta, Susanta Paul, Swarupananda Mukherjee, Nilanjan Sarkar, Arvind Kumar, Amrita Chakraborty, Anannya Bose, Atanu Hazra, Mainak Chakraborty   +8 more
wiley   +1 more source